3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
2
Skin Neoplasms
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Dacarbazine
4
pembrolizumab
3
binimetinib
3
Nivolumab
3
encorafenib
2
cemiplimab
2
Sirolimus
2
Ipilimumab
2
vitespin
1
trametinib
1
tilsotolimod
1
spartalizumab
1
oblimersen
1
linrodostat
1
lifileucel
1
gp100 Melanoma Antigen
1
dabrafenib
1
bempegaldesleukin
1
aldesleukin
1
Vinblastine
1
Vemurafenib
1
Tretinoin
1
Tacrolimus
1
Standard of Care
1
Sodium Chloride
1
Radiotherapy
1
Radiation
1
Interleukin-2
1
Interferon-alpha
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Skin Neoplasms
×
oblimersen
×
Clear all
NCT00518895
2011-11-07
AGENDA
Genta Incorporated
Phase 3
Completed
300 enrolled